Explore the fully interactive Multichannel News Release by clicking here: https://www2.multivu.com/amgen/9292951-en-la-la-anthony-amgen-partner-to-encourage-open-dialogue-about-plaque-psoriasis
In a recent interactive video, La La provides a personal and professional perspective on how plaque psoriasis has impacted her life. She emphasizes the importance of advocating for treatment options that suit her needs and helping others do the same.
Plaque psoriasis, often misunderstood as a skin condition, is actually an autoimmune disease originating from internal inflammation. It manifests as itchy, flaky patches on the skin, varying in coverage and severity among individuals.
Research indicates a disconnect between patients and doctors in assessing the severity of plaque psoriasis. While topical treatments like creams and ointments provide relief, they solely address symptoms and may be perceived as cumbersome by patients.
Dermatologist Meagen McCusker, M.D., M.S., FAAD, highlights the uniqueness of each patient’s experience with plaque psoriasis and the availability of diverse treatment approaches. She encourages open discussions with doctors about tailored treatment plans based on disease severity and individual lifestyle factors.
To engage with La La’s video, access resources for discussing plaque psoriasis treatment with healthcare providers, and learn about Otezla (apremilast), an oral treatment option, visit MomentsWithLaLa.com. Note that La La is not currently undergoing treatment or using Otezla.
Amgen is dedicated to assisting plaque psoriasis patients in accessing Otezla affordably. For more information, visit Otezla.com.
Psoriasis is a chronic condition characterized by rapid skin cell buildup, leading to red, scaly, and itchy patches. Globally, over 125 million people, including over 8 million in the United States, are affected by psoriasis, with about 80% having plaque psoriasis.
Otezla (apremilast) is an oral inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Since its FDA approval in 2014, Otezla has been prescribed to over 1 million patients worldwide.
Indications for Otezla include treatment of plaque psoriasis in adults suitable for phototherapy or systemic therapy, pediatric patients aged 6 and above with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with oral ulcers due to Behçet’s Disease.
For comprehensive safety information on Otezla, please refer to the full Prescribing Information available.
Amgen is a prominent biopharmaceutical company dedicated to delivering innovative medicines for challenging diseases. Recognized for its innovation, Amgen remains at the forefront of technological advancements and genetic data utilization to combat diverse health conditions.
In conclusion, stay informed about Amgen’s commitments, achievements, and advancements in the biopharmaceutical industry by visiting Amgen.com and following Amgen on various social media platforms. Note that the preceding statements by Amgen are based on current expectations and beliefs, subject to risks and uncertainties, detailed in regulatory filings.
